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Abstract
Aims Measurement of B-type natriuretic peptide (BNP) or N-terminal pro-BNP is recommended as part of the diagnostic
workup of patients with suspected heart failure (HF). We evaluated the diagnostic and prognostic utility of the novel urinary
proteomic classifier HF1, compared with BNP, in HF. HF1 consists of 85 unique urinary peptide fragments thought, mainly, to
reflect collagen turnover.
Methods and results We performed urinary proteome analysis using capillary electrophoresis coupled with mass spectrom-
etry in 829 participants. Of these, 622 had HF (504 had chronic HF and 118 acute HF) and 207 were controls (62 coronary heart
disease patients without HF and 145 healthy controls). The area under the receiver operating characteristic (ROC) curve (AUC)
using HF1 for the diagnosis of HF (cases vs. controls) was 0.94 (95% CI, 0.92–0.96). This compared with an AUC for BNP of 0.98
(95% CI, 0.97–0.99). Adding HF1 to BNP increased the AUC to 0.99 (0.98–0.99), P < 0.001, and led to a net reclassification
improvement of 0.67 (95% CI, 0.54–0.77), P < 0.001. Among 433 HF patients followed up for a median of 989 days, we ob-
served 186 deaths. HF1 had poorer predictive value to BNP for all-cause mortality and did not add prognostic information
when combined with BNP.
Conclusions The urinary proteomic classifier HF1 performed as well, diagnostically, as BNP and provided incremental diag-
nostic information when added to BNP. HF1 had less prognostic utility than BNP.
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Introduction
The diagnosis of heart failure (HF) is based on the presence of
typical symptoms and signs, supported by investigative evi-
dence. Measurement of a natriuretic peptide is the recom-
mended first-line investigation, with a normal plasma level
suggesting an alternative diagnosis and an elevated level an
indication for cardiac imaging.1 Demonstration of a structural
or functional cardiac abnormality on imaging confirms the di-
agnosis, clarifies the cause of HF, and is essential for selection
of the most appropriate therapy. Interpretation of natriuretic
peptide levels can, however, be difficult in certain groups of
patients, for example, those with atrial fibrillation, patients
who are obese, individuals with renal impairment, and
patients with pulmonary hypertension and right ventricular
dysfunction secondary to chronic lung disease. Patients with
HF with preserved ejection fraction (EF) (HFpEF) can be par-
ticularly difficult to diagnose, in part because they often have
one or more of these co-morbidities. Consequently, new bio-
markers that might aid the diagnosis of HF are of great inter-
est, especially if convenient for patients, if non-invasive, and
if cost-effective and time effective.
The urinary proteome is a potential source of novel diag-
nostic biomarkers. Proteomic analysis using capillary elec-
trophoresis coupled to mass spectrometry (CE-MS) has
previously been used to identify a panel of urinary pep-
tides, termed HF1, which was able to distinguish patients
with hypertension and diastolic impairment from healthy
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controls.2 The same classifier was able to identify those
with diastolic dysfunction in a sample of 745 people ran-
domly recruited from a Flemish population3 and distin-
guished patients with overt HF (16 hypertensive patients
in New York Heart Association class II or III) from healthy
controls (n = 16).2
Confirmation of these initial findings in a large cohort of
patients with HF is still outstanding. Therefore, our aim was
to test whether HF1 can discriminate clinical HF, both HF
with reduced EF (HFrEF) and HFpEF from healthy controls
and control subject with coronary heart disease (CHD).
We also assessed how this classifier compared with
B-type natriuretic peptide (BNP), the current ‘gold stan-
dard’ first-line test in the diagnostic pathway for HF, as well
as the prognostic value of this marker.
Methods
Participants
Three participant cohorts were studied: (i) outpatients with
chronic HF, (ii) patients hospitalized owing to HF, and (iii)
controls (patients with CHD and healthy volunteers). Diag-
nosis of HF (both acute and chronic) was made using the
European Society of Cardiology definition of HF recom-
mended at the time of recruitment.4,5 The chronic HF
cohort included patients from two separate
descriptive studies that enrolled participants between De-
cember 2006 and January 2009 and between March 2013
and December 2014.6,7 Patients with acute HF were en-
rolled in a descriptive study between January 2013 and De-
cember 2014.8,9 CHD and healthy controls were enrolled in
a descriptive study between March 2013 and December
2014.6 The studies were each approved by the West of
Scotland Research Ethics Committee, and each patient
consented to measurement of potential biomarkers in their
blood and urine.
All participants had measurement of plasma BNP and
a detailed echocardiographic examination, including mea-
surement of left ventricular EF using the Simpson
biplane method.10 Potential participants were excluded
from the healthy volunteer cohort if they had a
BNP > 100 pg/mL, and patients with suspected acute HF
were excluded if their BNP was <100 pg/mL at time of
screening.
Urinary proteomics analysis
Sample preparation and capillary electrophoresis coupled
with mass spectrometry analysis
Urine samples were collected on the same day that echo-
cardiograms and clinical assessment were performed and
stored at 80°C. Proteomic analysis was undertaken by op-
erators blind to participant group. CE-MS analyses were
performed using a P/ACE MDQ CE system (Beckman Coul-
ter, Fullerton, CA) online coupled to a micro-TOF MS
(Bruker Daltonics, Bremen, Germany) as described
previously.11,12 Mass spectrometric data were evaluated as
previously described,13 and the HF classifier, based on 85
urine peptides,2 was applied. The obtained peak lists char-
acterize each polypeptide by its molecular mass, normalized
CE migration time, and normalized signal intensity. HF1 pro-
teomic classifier is a normalized, dimensionless variable;
further details regarding the scoring of this proteomic clas-
sifier have previously been described.13
Further details of the urinary proteomic analysis are pro-
vided in the Supporting Information. Urine samples were col-
lected on the same day as other study assessments, and no
specific requirements were stipulated, for example, for an
early-morning sample or mid-stream sample.
Statistical analysis
Baseline characteristics are presented according to partici-
pant group. Continuous variables are described as median
and inter-quartile range, and categorical variables as counts
and percentages. Boxplots are presented for the urinary clas-
sifier HF1 and split by the same groups.
Correlations of HF1 with log BNP, EF, and left ventricular
size were calculated using Pearson’s coefficient; and
scatterplots are provided for each comparison. Receiver op-
erating characteristic (ROC) was used to evaluate the diag-
nostic utility of HF1 as a continuous measure for
discriminating between HF patients and controls, first as indi-
vidual predictors and, then, as linear combinations, derived
using logistic regression. C-Statistics were calculated. The
net reclassification improvement (NRI) was calculated to
compare the predictive probabilities of models using BNP
alone and BNP with HF1.
Patients who provided consent were followed up for vi-
tal status by record linkage through the Information Ser-
vices Division of National Services Scotland. This record
linkage has previously been described and provides
near-complete follow-up with rare loss to follow-up.14 For
patients with follow-up data, HF1 was grouped into tertiles,
and Kaplan–Meier survival curves were generated for time
to all-cause death in relation to each tertile. P-values for
differences in curves were obtained using log rank tests.
A Cox proportional hazard model was fitted using the
Meta-analysis Global Group in Chronic Heart Failure
(MAGGIC) risk score as the only covariate.15 To assess the
prognostic value of HF1, this model was extended to in-
clude this classifier as a continuous covariate. Hazard ratios,
95% confidence intervals (CIs), and P-values are reported
for each model.
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Results
We performed urinary proteome analysis by CE-MS in 829
participants. Of these, 622 had HF (504 had chronic HF and
118 acute HF) and 207 were controls (62 with CHD and 145
healthy volunteers).
Baseline demographics of all three cohorts are shown in
Table 1. Patients with HF [median age 72 (66–80) years] were
older than controls [66 (63–72) years]. Higher proportions of
patients with HF and CHD controls were men, compared with
the healthy volunteers. Renal function was better and
haemoglobin was higher in healthy volunteers and CHD con-
trols than in patients with HF. Liver function was similar in all
cohorts.
Of the patients with chronic HF, 430 (85%) had HFrEF; of
those with acute HF, the number with HFrEF was 79 (67%).
There was a stepwise increase in BNP concentration from
healthy controls (who had the lowest median BNP at
26 pg/mL) to patients with acute HFrEF (who had the highest
median concentration at 744 pg/mL).
The results of urinary proteomic analysis and application
of the HF1 classifier are shown in Table 1 and Figure 1. Pa-
tients with HF had higher values for HF1 than had both the
CHD controls and healthy volunteers. Patients with acute
HF (both HFrEF and HFpEF) had the highest levels of HF1
(higher than those of patients with chronic HF). Scatterplots
of HF1 and BNP, EF, and left ventricular size are shown in
Figure 2. There were positive correlations between HF1
and BNP (r = 0.40, P < 0.001) and ventricular size, as mea-
sured by left ventricular end-diastolic dimension (r = 0.32,
P < 0.001) and an inverse correlation between HF1 and
EF (r = 0.52, P < 0.001).
Diagnostic utility of HF1
The ROC curve for HF1, comparing definite cases of HF with
control participants (both CHD controls and healthy volun-
teers), is shown in Figure 3. The area under the ROC (AUC)
for HF1 was 0.94 (95% CI, 0.92–0.96). This compared with
an AUC for BNP of 0.98 (95% CI, 0.97–0.99). Adding HF1 to
BNP resulted in AUC of 0.99 (95% CI, 0.98–0.99). The addition
of HF1 to BNP resulted in an NRI of 0.67 (95% CI, 0.54–0.78),
P < 0.001.
When chronic HF cases (i.e. acute HF cases were excluded
from analysis) were compared with controls only (Figure 4),
the AUC for HF1 was 0.93 (95% CI, 0.91–0.95); the corre-
sponding AUC for BNP was 0.97 (95% CI, 0.96–0.98). Adding
HF1 to BNP resulted in an AUC of 0.99 (0.98–0.99). The addi-
tion of HF1 to BNP resulted in an NRI of 0.71 (0.58–0.84),
P < 0.001.
When HF cases were compared with CHD controls only
(Figure 5), the AUC for HF1 was 0.85 (95% CI, 0.80–0.90);
the corresponding AUC for BNP was 0.96 (95% CI, 0.94–
0.97). Adding HF1 to BNP resulted in an AUC of 0.97 (0.96–
0.98). The addition of HF1 to BNP resulted in an NRI of 0.68
(0.40–0.97), P < 0.001.
Survival analysis
Of the 622 patients with HF, 433 patients provided consent to
be followed up for vital status using long-term record linkage.
Follow-up for vital status of the healthy and ischaemic heart
disease controls was not available; and these subjects were
therefore not included in the survival analyses. During a me-
dian follow-up of 989 days, 186 patients died. Kaplan–Meier
estimates of survival by tertile of HF1 are shown in Figure
6, with a significant association between HF1 and mortality
(P = 0.004). The additive value of HF1 to the MAGGIC prog-
nostic risk score and to BNP is shown in Table 2. HF1 did
not retain prognostic predictive value in this cohort when
added to either the MAGGIC risk score or BNP.
Discussion
We describe the diagnostic and prognostic performance and
potential utility of a novel urinary proteomic panel, HF1, in
a large cohort of patents with HF, compared with healthy
and CHD controls.
The first important observation from our study is the sim-
ilarity in diagnostic utility of HF1 and BNP. The high AUC for
BNP in our study is similar to that reported in previous stud-
ies assessing the diagnostic utility of BNP. In the Breathing
Not Properly study, where 1586 patients who presented to
an emergency department with acute dyspnoea had BNP
analysed and a clinical diagnosis of HF was adjudicated by
two cardiologists, BNP had an AUC of 0.91 (95% CI, 0.90–
0.93).16 An elevated BNP of >100 pg/mL was the strongest
independent predictor of having a diagnosis of HF, with an
odds ratio of 30. Similarly, high AUCs have been reported
for N-terminal pro-BNP (NT-proBNP), for example, in the
ProBNP Investigation of Dyspnea in the Emergency depart-
ment study (PRIDE), where 600 patients presenting with
acute dyspnoea had NT-proBNP assessed.17 The AUC for
NT-proBNP in PRIDE was 0.94, and again elevated
NT-proBNP was the strongest predictor of a diagnosis of HF
with an odds ratio of 44. The AUC in the present study was
probably particularly high because we used BNP to include
and exclude participants; that is, patients with HF had to have
an elevated BNP, and normal controls a low BNP, to be
eligible.7,8 Because of this, HF1 was at a potential disadvan-
tage, yet had a similar AUC to BNP and was additive when
combined with BNP, with the combined AUC reaching 0.99.
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The peptides in HF1 sequenced to date are not related to
BNP and mainly reflect collagen fragments.2 This is supported
by the moderate association between BNP and HF1, and the
additive value of this proteomic panel to BNP. HF1 is there-
fore a marker of a different aspect of the disease process in
HF. Where BNP is a compensatory up-regulated mechanism,
with BNP released in response to volume expansion and/or
pressure overload resulting in increased wall stress, HF1
probably reflects changes in the extracellular matrix and,
therefore, interstitial fibrosis.2 Although HF is a clinical
syndrome, with a multitude of causes and different clinical
phenotypes, myocardial interstitial fibrosis is a common path-
ophysiological process in most, if not all, of these.18 Future
studies should build upon our findings by assessing the asso-
ciation between the proteomic classifier HF1 and direct and
indirect markers of myocardial interstitial fibrosis such as
endomyocardial biopsy and cardiac magnetic resonance
(CMR) imaging.
Myocardial interstitial fibrosis is associated with worse clin-
ical outcomes in patients with HFrEF and HFpEF.19,20
Figure 1 (A) Boxplots of HF1 urinary classifier by HF and control groups. HF1, heart failure 1 urinary proteomic classifier; HFpEF, heart failure with pre-
served ejection fraction; HFrEF, heart failure with reduced ejection fraction; IHD, ischaemic heart disease. (B) Boxplots of BNP by HF and control
groups. BNP, B-type natriuretic peptide; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction;
IHD, ischaemic heart disease.
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Figure 2 (A) Scatterplot HF1 and BNP. HF1, heart failure 1 urinary proteomic classifier; BNP, B-type natriuretic peptide. Cases presented include acute
and chronic HF and control subjects. (B) Scatterplot HF1 and LVEDD. HF1, heart failure 1 urinary proteomic classifier; LVEDD, left ventricular
end-diastolic dimension. Cases presented include acute and chronic HF, and control subjects. (C) Scatterplot HF1 and EF. HF1, heart failure 1 urinary
proteomic classifier; EF, ejection fraction. Cases presented include acute and chronic HF and control subjects.
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Therefore, the proteomic marker HF1 should also have been
associated with poorer prognosis in our cohort. This is what
we found, although the relationship between HF1 and
prognosis was not as strong as that with diagnosis. Although
HF1 was an independent predictor of all-cause mortality, it
had a lower predictive value to BNP for all-cause mortality
and did not add prognostic information when combined with
BNP. Neither BNP nor HF1 improved upon the prognostic in-
formation provided by the MAGGIC risk score. So our findings
suggest that, in terms of prognosis, HF1 may be an alterna-
tive to BNP but has no added value. Further studies in larger
cohorts are required to assess the predictive value of HF1
with more confidence.
Study strengths and limitations
The strengths of our study were that the different cohorts of
HF patients and controls were enrolled at a single investiga-
tive centre and each participant had a BNP level assayed
and an echocardiographic measurement of EF using the
Simpson biplane method. Both acute and chronic HF patients
were included in our analysis as were patients with HFpEF
and HFrEF. Limitations included that this was a retrospective
analysis. Although a detailed echocardiogram was performed
in each patient, only one measure of function (EF) and one
measure of remodelling (left ventricular size) were included
in the analysis. Further studies utilizing more advanced imag-
ing techniques, such as myocardial strain or extracellular vol-
ume, using echocardiography and CMR, would provide
further insights into the potential source of high HF1 in pa-
tients with HF. We studied only one clinical outcome,
Figure 3 ROC for HF1 protein classifier, BNP, and HF1 + BNP: HF (both
acute and chronic) vs. control (both CHD and healthy). BNP, B-type natri-
uretic peptide; CHD, coronary heart disease; HF1, heart failure 1 urinary
proteomic classifier; ROC, receiver operating characteristic.
Figure 4 ROC for HF1 protein classifier, BNP, and HF1 + BNP: chronic HF
vs. control (both CHD and healthy). BNP, B-type natriuretic peptide; CHD,
coronary heart disease; HF1, heart failure 1 urinary proteomic classifier;
ROC, receiver operating characteristic.
Figure 5 ROC for HF1 protein classifier, BNP, and HF1 + BNP: HF (both
acute and chronic) vs. IHD control. BNP, B-type natriuretic peptide;
CHD, coronary heart disease; HF1, heart failure 1 urinary proteomic classi-
fier; IHD, ischaemic heart disease; ROC, receiver operating characteristic.
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all-cause death; and cardiac biomarkers may not predict
all-cause mortality as well as death due to cardiovascular
causes. We did not have information of HF hospitalization,
which is also predicted well by most cardiac biomarkers.
Although efforts were made to collect urine samples on
the same day as other study assessments, this may not have
been the case for every participant, although this was not re-
corded. There was no standard operating procedure for col-
lection of urine; specifically, there were no requirements
made for an early-morning or mid-stream sample. Although
urinary peptides undergo changes throughout the day, by
using a urinary proteomic classifier composed of multiple
peptide (such as in our study), variance based on time of sam-
ple is reduced to non-significant levels.13
Conclusions
The urinary proteomic classifier HF1 is a novel biomarker that
discriminates between patients with HF and both healthy
controls and patients with CHD but no HF. Diagnostically,
HF1 performed as well as BNP and provided incremental diag-
nostic information when added to BNP. HF1 also predicted
all-cause mortality but did not do this better than BNP or
add to the prognostic value of BNP.
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